清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Tissue-Resident Memory T Cells in Cancer Immunosurveillance

免疫监视 肿瘤免疫学 免疫系统 免疫学 癌症 免疫疗法 生物 医学 内科学
作者
Simone L. Park,Thomas Gebhardt,Laura K. Mackay
出处
期刊:Trends in Immunology [Elsevier BV]
卷期号:40 (8): 735-747 被引量:171
标识
DOI:10.1016/j.it.2019.06.002
摘要

TRM cells are non-recirculating immune cells that reside in peripheral tissues where they can protect against local infections and cancer. CD69+CD103+ TRM-like cells accumulate in various human solid cancers where they have been associated with improved disease outcomes and patient survival. Vaccine-generated TRM cells can protect against tumor challenge independently of TCIRC cells. TRM cells may mediate tumor protection by promoting tumor-immune equilibrium through the secretion of cytokines and/or via CD103-enhanced tumor cell killing. TRM cells express inhibitory checkpoint molecules and may serve as potential targets for cancer immunotherapy. Following their activation and expansion in response to foreign threats, many T cells are retained in peripheral tissues without recirculating in the blood. These tissue-resident CD8+ memory T (TRM) cells patrol barrier surfaces and nonlymphoid organs, where their critical role in protecting against viral and bacterial infections is well established. Recent evidence suggests that TRM cells also play a vital part in preventing the development and spread of solid tumors. Here, we discuss the emerging role of TRM cells in anticancer immunity. We highlight defining features of tumor-localizing TRM cells, examine the mechanisms through which they have recently been shown to suppress cancer growth, and explore their potential as future targets of cancer immunotherapy. Following their activation and expansion in response to foreign threats, many T cells are retained in peripheral tissues without recirculating in the blood. These tissue-resident CD8+ memory T (TRM) cells patrol barrier surfaces and nonlymphoid organs, where their critical role in protecting against viral and bacterial infections is well established. Recent evidence suggests that TRM cells also play a vital part in preventing the development and spread of solid tumors. Here, we discuss the emerging role of TRM cells in anticancer immunity. We highlight defining features of tumor-localizing TRM cells, examine the mechanisms through which they have recently been shown to suppress cancer growth, and explore their potential as future targets of cancer immunotherapy. transfer of preactivated and/or tumor-specific immune cells into a patient to treat cancer. ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1); cell-surface molecule that hydrolyzes extracellular ATP; usually marks activated or exhausted T cells. subset of memory T cells that migrate through blood and secondary lymphoid organs; characterized by heightened expression of L-selectin (CD62L) and CCR7. T cell engineered to express a modified T cell receptor (TCR) specific for a protein expressed by cancer cells that differs from that recognized by their endogenous TCR. memory T cells that continuously migrate through blood and secondary lymphoid organs; includes both effector and central memory T cell subsets. subset of memory T cells that migrate through peripheral tissues and the blood; characterized by low expression of both CD62L and CCR7. process through which immune cells completely kill and eradicate cancerous cells. process during which epithelial or cancerous cells lose cell–cell adhesion properties and acquire heightened invasive and metastatic potential. process through which immune cells suppress cancer growth without completely removing tumor cells from the body. state of T cell dysfunction characterized by a loss of effector function resulting from unrelenting antigen stimulation and/or chronic infection. sphingosine 1-phosphate receptor antagonist that enforces lymphocyte retention within lymphoid organs by blocking their egress. DNA-binding transcription factor encoded by the Znf638 gene; a master regulator of tissue residency in both innate and adaptive lymphocytes. drug treatments (usually antibody therapies, e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) designed to activate or enhance anticancer immune responses. evolutionary process comprising elimination, equilibrium, and escape phases through which immune cells select for less immunogenic tumor cell clones that arise during tumor progression. point of contact between a lymphocyte and an antigen-presenting or target cell. newly generated tumor-specific antigen that arises through mutations occurring during cancer growth. experimental process during which the circulatory systems of two animals are joined to investigate migratory properties of immune cells. cell-surface immune checkpoint molecule encoded by the Pdcd1 gene that negatively regulates T cell activation and function. DNA-binding transcription factor encoded by the Tcf7 gene, involved in T cell differentiation and expressed by proliferative or stem-like subsets of tumor-infiltrating T cells. cell-surface immune checkpoint molecule encoded by the Havcr2 gene and associated with T cell dysfunction. T helper 1; CD4+ T cells or immune response involving effector molecules canonically tailored to combat intracellular pathogens or cancerous cells, including IFN-γ and TNF. T helper 2; CD4+ T cells or immune response involving effector molecules canonically tailored to combat parasites; may be associated with allergy, including IL-4, IL-5, and IL-13. T helper 17; CD4+ T cells or immune response involving effector molecules canonically tailored to combat extracellular bacteria and that may be associated with autoimmune diseases, including IL-17. subset of memory T cells that reside permanently within peripheral or nonlymphoid tissues, without recirculating in blood. space and factors within and surrounding cancer cells, including stromal and immune cells that infiltrate a tumor and the molecules they produce. cell-surface molecule that binds collagen IV and may be involved in T cell migration, cell adhesion, and cytotoxic activity. autoimmune disease in which immune cells target and kill melanocytes, leading to depigmentation of the skin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
喜悦半莲完成签到,获得积分10
6秒前
psm完成签到 ,获得积分10
8秒前
30秒前
失眠的修杰完成签到,获得积分10
36秒前
39秒前
acat完成签到 ,获得积分10
39秒前
超级无敌万能小金毛完成签到,获得积分10
39秒前
42秒前
单薄涵梅完成签到,获得积分10
1分钟前
老戎完成签到 ,获得积分10
1分钟前
爱笑的笑旋完成签到,获得积分10
1分钟前
爆米花的应助被科研通管家采纳,获得10
1分钟前
nnn关闭了nnn的文献求助
1分钟前
科研民工完成签到,获得积分10
1分钟前
Zyou完成签到,获得积分10
1分钟前
落后的雨筠完成签到,获得积分10
1分钟前
1分钟前
大意的之柔完成签到,获得积分10
2分钟前
依然灬聆听完成签到,获得积分10
2分钟前
会发光的小叶子完成签到,获得积分10
2分钟前
漂亮傲云完成签到,获得积分10
2分钟前
勤劳寒松完成签到,获得积分10
2分钟前
风趣馒头完成签到,获得积分10
2分钟前
激动的发卡完成签到,获得积分10
2分钟前
李健的应助被科研通管家采纳,获得10
3分钟前
Maestro_S的应助被科研通管家采纳,获得10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
时尚的青易完成签到,获得积分10
3分钟前
感性的鸡完成签到,获得积分10
3分钟前
嘻嘻完成签到,获得积分10
4分钟前
英俊的青烟完成签到,获得积分10
4分钟前
marine完成签到 ,获得积分10
4分钟前
4分钟前
向连虎发布了新的文献求助10
4分钟前
4分钟前
超级诗桃完成签到,获得积分10
4分钟前
绛仙旧友完成签到,获得积分10
4分钟前
无辜的水蜜桃完成签到,获得积分10
4分钟前
liunahan完成签到 ,获得积分10
5分钟前
JUN完成签到,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166338
求助须知:如何正确求助?哪些是违规求助? 9559484
关于积分的说明 21750435
捐赠科研通 7757131
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553469
邀请新用户注册赠送积分活动 2473812